Prognosis in Myeloma
- 1 September 1994
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 69 (9) , 895-902
- https://doi.org/10.1016/s0025-6196(12)61797-2
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Prognostic factors in multiple myeloma: role of ?2-microglobulin and thymidine kinaseJournal of Molecular Medicine, 1993
- Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]Blood, 1993
- Impact of active and passive exclusions on the results of a clinical trial in multiple myelomaBritish Journal of Haematology, 1992
- A plea to overcome the concept of “staging” and related inadequacy in multiple myelomaEuropean Journal of Haematology, 1991
- Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.Journal of Clinical Oncology, 1991
- Prognostic factors and classification in multiple myelomaBritish Journal of Cancer, 1989
- Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myelomaBlood, 1988
- Ploidy and proliferative characteristics in monoclonal gammopathiesBlood, 1982
- Pretreatment tumor mass, cell kinetics, and prognosis in multiple myelomaBlood, 1980
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975